GlaxoSmithKline plc Vs AstraZeneca plc — Which Is The Better Bet For Income And Growth?

GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN) are both great companies, but which one should you choose?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.


The FTSE 100’s two pharmaceutical giants, AstraZeneca plc (LSE:AZN) (NYSE:AZN.US) and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK.US) are facing many challenges in the years ahead. But which one is the better choice for income and growth during the next few years? 

Growth in a key region

AstraZeneca and Glaxo both released full-year 2013 results last week and AstraZeneca’s were highly impressive. In particular, one region where the company is pulling ahead of its close peer is in China, which is without a doubt a key growth market for both companies.

Unfortunately, during 2013 Glaxo was subject to a significant amount of negative press within China, causing the company’s sales to slump. Specifically, during the third and fourth quarter of last year Glaxo’s sales within China declined 61% and 29% respectively. On the other hand, AstraZeneca has seen its Chinese sales surge, 13% and 21% in the third and fourth quarters of last year respectively.

But it’s not all about China

However, it’s not all about China and we need to take into account other factors that may influence these companies. For example, Glaxo’s pipeline of treatments has long been the company’s most attractive quality, especially when the industry as a whole is suffering from the so called ‘patent cliff’.

Glaxo, in particular, had five new drugs approved during 2013 and forty more are in the late stage processes of coming to market. That being said, AstraZeneca is also driving hard to expand its pipeline of new treatments and the company has reportedly doubled its pipeline of late stage treatments during the past year. Actually, faster than expected pipeline growth has lead AstraZeneca’s management to declare that the company is likely to return to growth sooner than expected, as new treatments take up the slack of falling legacy drug sales.   

What about those shareholder payouts?

Of course, one of the most attractive traits of these pharma companies is their shareholders returns, or to be specific, their hefty dividend yields.  This where Glaxo really pulls ahead of AstraZeneca, as the company has a robust free cash flow, with plenty of cash available to return to investors.

For example, for the full-year 2013, Glaxo generated a free cash flow of more than £7.5 billion, of which the company returned more than £5 billion to investors through both dividends and share repurchases. Unfortunately, AstraZeneca only generated a free cash flow of $4.5 billion for full-year 2013, of which it returned around $3.6 billion to investors via the dividend.

So all in all, Glaxo’s shareholder payouts look safer and more attractive than those of AstraZeneca.

Foolish summary

Although AstraZeneca is putting in an impressive performance, Glaxo remains my favourite company of the pair. Overall, I feel that thanks to its hefty free cash flow and pipeline of treatments under development GlaxoSmithKline is your bettet bet for income and growth during the next few years. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Here’s how I’d aim to build a £50K SIPP into a £250K retirement fund

Our writer outlines the approach he would take to try and increase the value of his SIPP multiple times in…

Read more »

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »